COMMUNIQUÉS West-GlobeNewswire

AdipoPharma Advances PATAS into Phase 1b Clinical Trial in Patients with Type 2 Diabetes
27/10/2026
First participants with Type 2 diabetes dosed in multiple ascending dose (MAD) study evaluating AdipoPharma’s first-in-class insulin sensitizer Advancement follows successful completion of the single ascending dose (SAD [...]
1104Health and Johns Hopkins Researchers Present Data on Physician Collaboration Across Community and Academic Oncology
27/10/2026
Across 24 oncology organizations, findings highlight new physician relationships, rapid access to subspecialty expertise, and changes in patient management BALTIMORE, Oct. 27, 2026 (GLOBE NEWSWIRE) -- 1104Health, which [...]
Transactions in connection with share buy-back program
27/10/2026
Company announcement no. 43 - 26 27 October 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Newsweek classe le KFSH parmi les 4 % d’hôpitaux les plus avancés au monde en matière de maturité numérique et d’IA
27/10/2026
RIYAD, Arabie saoudite, 27 oct. 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSH) est l’un des 15 seuls hôpitaux au monde à avoir obtenu à la fois la note maximale de cinq rubans [...]
Immuron continued quarterly sales growth
27/10/2026
Sales Highlights (unaudited): Global Q1 sales AUD$2.2 million up 9% on prior comparative period (pcp) Q1 sales up 5% on prior quarter Australia Q1 sales AUD$1.8 million up 14% on prior comparative period (pcp) Q1 sales [...]
Nautilus Biotechnology Reports Third Quarter 2026 Financial Results
27/10/2026
SEATTLE, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended [...]
Nautilus to Measure Proteoforms Driving Alzheimer’s Disease and Cancer in ARPA-H-Funded SEEDS Consortium
27/10/2026
Nautilus expects to receive up to $6 million to bring its Voyager™ Platform to a multidisciplinary team integrating protein science, AI, and computational modeling to develop new diagnostics and therapeutics SEATTLE, [...]
Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma
27/10/2026
- Results Demonstrated Breadth and Rapidity of Response to ATI-052 in Heterogeneous Patient Populations; Pharmacodynamic Results Demonstrated Potential for Additivity/Synergy of Targeting TSLP and IL-4R α - - Rapid and [...]
Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026
27/10/2026
MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) today announced that Azeem Latib, MD, will present the first [...]
Merakris Advances Potentially Pivotal MTX-001 Phase 2/3 Strategy Following FDA Pre-IND Meeting
27/10/2026
FDA indicates proposed double-blind Phase 2/3 design could be considered adequate and well controlled as Merakris prepares its first commercial-pilot GMP drug lot for a potentially pivotal trial. RESEARCH TRIANGLE PARK [...]
Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants
27/10/2026
WAYNE, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
27/10/2026
Third quarter revenue of $209 million, a year-over-year increase of 11% as reported and 12.5% organic Closed BioLife acquisition, which fast-tracks Repligen’s leadership and offering in high-growth cell therapy market [...]
NeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026
27/10/2026
CARMEL, Ind., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]
Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain
27/10/2026
TONMYA improved Fibromyalgia Impact Questionnaire-Revised (FIQR) symptoms and function scores versus placebo in both domains at Week 14 in RELIEF and RESILIENT Phase 3 pivotal studies Tonix commercially launched TONMYA [...]
Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience
27/10/2026
Distinguished scientists bring expertise spanning stem cell biology, regenerative medicine, aging research, neuroscience and small molecule chemistry TORONTO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. ( [...]
Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026
27/10/2026
NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that [...]
Hormone-Free Menopause Supplement for Perimenopause Through Postmenopause Now Available From Calroy Health Sciences
27/10/2026
The daily formula pairs two ingredients, each with published research in women in mid-life or after menopause* Scottsdale, AZ, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Selentra HP™, powered by FEM-936™, a hormone-free [...]
Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET
27/10/2026
WARREN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' [...]
Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026
27/10/2026
PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating [...]

Pages